GEN Exclusives

More »

Feature Articles

More »
Feb 15, 2011 (Vol. 31, No. 4)

IDBS Set to Optimize Bioprocesses at Lonza

Data-Management and Execution System Will Be Used to Manage Mammallian Cell Culture Data

  • Data-Management Technology

    “BPES is based upon IDBS’ data-management technology,” noted Kipling, adding that it is a solution that can be rapidly deployed to streamline and optimize bioprocess workflows.

    “This allows data to be stored in context and more effectively shared between groups, deployed as a source of corporate knowledge, and used to monitor and improve process development and biological production operations,” he said.

    According to Kipling, this solution enables organizations to:

    • lessen the amount of repeated work by more than 10% with better access to current and past data and knowledge;

    • reduce unnecessary load on fixed capital assets;

    • speed up development, technology transfer and continuous improvement;

    • troubleshoot processes and perform root-cause analysis in minutes rather than weeks;

    • implement a knowledge and data management platform to support ICH Q10, QbD, and process understanding;

    • compare data and perform process intelligence queries to help improve and optimize processes;

    • trace and optimize component usage and equipment performance; and,

    • dramatically reduce the time assiciated with technology transfer.

    Lonza officials said that it was because of these advantages and capabilities that they chose the IDBS system.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?